Viewing Study NCT04502069


Ignite Creation Date: 2025-12-24 @ 11:06 PM
Ignite Modification Date: 2026-01-01 @ 7:07 AM
Study NCT ID: NCT04502069
Status: WITHDRAWN
Last Update Posted: 2020-08-11
First Post: 2020-07-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen
Sponsor: RedHill Biopharma Limited
Organization:

Study Overview

Official Title: Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen But Not Mechanical Ventilation
Status: WITHDRAWN
Status Verified Date: 2020-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: To be replaced with a randomized placebo-controlled study.
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: Opaganib-RHB
Brief Summary: Patients diagnosed with COVID-19 infection will be offered treatment with Opaganib, 500 mg Q12 hours. Opaganib will be continuously administered for up to 2 weeks, until discharged on room air (if earlier than 2 weeks).
Detailed Description: Patients diagnosed with COVID-19 infection by nasopharyngeal viral swab, classified as severe disease, category 5, by the WHO Ordinal Scale For Clinical Improvement (who require oxygen support by high flow nasal cannula but do not require mechanical ventilation) at the time of initiation of therapy will be offered treatment with Opaganib, 500 mg Q12 hours.

Opaganib will be continuously administered for up to 2 weeks, until discharged on room air (if earlier than 2 weeks), upon voluntary withdrawal is initiated by the patient or when the physician decides that it is not in the patient's best interest to continue.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: